NAMSA, InspireMD Partner to Accelerate New Product Development

NAMSA and InspireMD Inc. have formed a strategic outsourcing partnership to accelerate medical device development and commercialization. 

The collaboration enables InspireMD to tap into NAMSA’s resources and expertise to expedite product development and establish a more efficient path to market. “InspireMD has always sought ways to safely and efficiently accelerate product development through strategic outsourcing partners, and we have now found what we believe to be the ideal partner in NAMSA,”InspireMD CEO Marvin Slosman said. “We look forward to establishing a more efficient path to market through NAMSA’s expertise, experience and established relationships with regulatory authorities. With NAMSA’s support, we can put more emphasis on integrating MicroNet technology to develop products that are part of the new industry standard for sustained embolic/neurovascular protections and stroke prevention. Our entire team looks forward to partnering with NAMSA as we continue to expand our presence globally and bring much-needed medical technology advancements to patients around the world.” 
 
Founded in 2005, InspireMD became publicly traded in 2011. The company develops and commercializes the CGuard EPS stent platform and related delivery systems that provide sustained embolic and neurovascular protections. These products also include medical technologies for stroke prevention and carotid artery disease (CAD) treatments. With its proprietary MicroNet technology, InspireMD is focused on changing the carotid and neurovascular market by working to make CGuard EPS the standard of care in CAD while expanding its portfolio of solutions and pursuing applications of its MicroNet technology in other peripheral indications.
 
“We are thrilled that InspireMD has selected NAMSA as their strategic outsourcing partner of choice,” NAMSA CEO Dr. Christophe Berthoux said. “NAMSA’s mission is to deliver best-in-class global MedTech solutions through our people, expertise and technology and this collaboration is quintessential to this endeavor. With increasing demand to find trusted outsourcing partners to accelerate efficient clinical development of life-changing medical products, we are well positioned to work together in this joint venture. Leveraging NAMSA’s full continuum of development services, combined with our deep-rooted cardiovascular and neurovascular expertise, we look forward to helping accelerate InspireMD’s new product development efforts.” 
 
A key driver of success for medtech sponsors in the product development process is speed to market. Many companies are currently experiencing longer development timelines to accommodate a greater number of clinical trials for Class II and III products due to more complex regulatory and clinical requirements. Consequently, trial sponsors are increasingly seeking strategic outsourcing partners with proven, trusted track records of decreasing development costs, providing multiple resource efficiencies, accelerating timelines and providing immediate access to therapeutic expertise and knowledge. 

Helping medical device sponsors improve healthcare since 1967, NAMSA is a medtech contract research organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA helps its partners achieve successful development and commercialization outcomes.